{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:02:45Z","timestamp":1774558965912,"version":"3.50.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001336","name":"University of the Witwatersrand, Johannesburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s15010-025-02682-x","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:35:20Z","timestamp":1769067320000},"page":"575-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural mimics of SARS-CoV-2"],"prefix":"10.1007","volume":"54","author":[{"given":"Natasha","family":"Killassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohube Betty","family":"Maepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2682_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, Doremalen N, Falzarano D, Munster V. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"2682_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Lai S, Poon L, Guan Y, Yam L, Lim W. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319\u201325.","journal-title":"Lancet"},{"key":"2682_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2019","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2019;382:727\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"2682_CR4","first-page":"157","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157\u201360.","journal-title":"Acta Biomed"},{"key":"2682_CR5","doi-asserted-by":"crossref","unstructured":"Ikejezie J, Miglietta A, Nezu I, Adele S, Higdon M, Feikin D et al. Informing the pandemic response: the role of the who\u2019s COVID-19 weekly epidemiological update. BMJ Glob Health. 2024;9(4).","DOI":"10.1136\/bmjgh-2023-014466"},{"key":"2682_CR6","doi-asserted-by":"crossref","unstructured":"Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H et al. SARS-CoV-2 Spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(372).","DOI":"10.1038\/s41467-020-20653-8"},{"issue":"6","key":"2682_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21(6):803\u201312.","journal-title":"Lancet Infect Dis"},{"key":"2682_CR8","doi-asserted-by":"crossref","unstructured":"Kushnir A, Mueller S, Tasker S, Coleman R. 577. COVI VACTM,a live attenuated COVID-19 vaccine; provides single dose protection against heterologous challenge with SARS-CoV-2 beta (B.1.351) in the Syrian golden hamster model. Infect Dis. 2021;8.","DOI":"10.1093\/ofid\/ofab466.775"},{"key":"2682_CR9","unstructured":"Pfizer, Pfizer. and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints [Internet]. 2020. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine"},{"key":"2682_CR10","unstructured":"World Health Organisation. Interim recommendations for use of the inactivated COVID 19 vaccine, CoronaVac, developed by Sinovac. Guidance. WHO; 2021."},{"key":"2682_CR11","unstructured":"WHO. COVID-19 vaccine (recombinant, adjuvanted. NVX-CoV2373, COVOVAXTM. NUVAXOVIDTM; 2022."},{"key":"2682_CR12","doi-asserted-by":"publisher","first-page":"111998","DOI":"10.1016\/j.celrep.2023.111998","volume":"42","author":"A Tauzin","year":"2023","unstructured":"Tauzin A, Nicolas A, Ding S, Benlarbi M, Medjahed H, Chatterjee D, et al. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Rep. 2023;42:111998.","journal-title":"Cell Rep"},{"issue":"8S","key":"2682_CR13","first-page":"2","volume":"52","author":"B Lina","year":"2022","unstructured":"Lina B, Bauer J. SARS-CoV-2 genetic diversity: its impact on vaccine efficacy. Infect now. 2022;52(8S):2\u20133.","journal-title":"Infect now"},{"key":"2682_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","volume":"181","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Holmes E. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181:223\u20137.","journal-title":"Cell"},{"key":"2682_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey WT, Carabelli A, Jackson B, Gupta R, Thomson E, Harrison E, et al. SARS-CoV-2 variants, Spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409\u201324.","journal-title":"Nat Rev Microbiol"},{"key":"2682_CR16","doi-asserted-by":"crossref","unstructured":"Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Public. 2020;44.","DOI":"10.26633\/RPSP.2020.40"},{"issue":"6","key":"2682_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, Parida S, Lingaraju M, Kesavan M, Kumar D, Singh R. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479\u2013508.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"2682_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in High-Risk patients. Clin Infect Dis. 2023;76(3):342\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2682_CR19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/cid\/ciad460","volume":"77","author":"E Mozaffari","year":"2023","unstructured":"Mozaffari E, Chandak A, Gottlieb R, Chima-Melton C, Read S, Jiang H, et al. Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice. Clin Infect Dis. 2023;77(12):1626\u201334.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2682_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Bernal","year":"2022","unstructured":"Bernal A, da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","journal-title":"N Engl J Med"},{"issue":"7","key":"2682_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2201662","volume":"387","author":"C Bramante","year":"2022","unstructured":"Bramante C, Huling J, Tignanelli C, Buse J, Liebovitz D, Nicklas J, et al. Randomized trial of Metformin, Ivermectin, and fluvoxamine for Covid-19. N. Engl J Med. 2022;387(7):599\u2013610.","journal-title":"Engl J Med"},{"key":"2682_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41592-023-01769-3","volume":"20","author":"K Gangavarapu","year":"2023","unstructured":"Gangavarapu K, Latif A, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023;20:512\u201322.","journal-title":"Nat Methods"},{"key":"2682_CR23","doi-asserted-by":"crossref","unstructured":"Lancet. Emerging SARS-CoV-2 variants: shooting the messenger. Lancet Infect Dis. 2022;22(1).","DOI":"10.1016\/S1473-3099(21)00770-2"},{"issue":"1","key":"2682_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/v16010102","volume":"16","author":"A Bartel","year":"2024","unstructured":"Bartel A, Grau J, Bitzegeio J, Werber D, Linzer N, Schumacher V, et al. Timely monitoring of SARS-CoV-2 RNA fragments in wastewater shows the emergence of JN.1 (BA.2.86.1.1, clade 23I) in Berlin. Ger Viruses. 2024;16(1):102.","journal-title":"Ger Viruses"},{"issue":"3","key":"2682_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.resinv.2025.03.001","volume":"63","author":"N Miyashita","year":"2025","unstructured":"Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ito T. Characteristics of the 11th wave by SARS-CoV-2 KP.3 subvariant: Re-increase in pneumonia severity. Respir Investig. 2025;63(3):401\u20134.","journal-title":"Respir Investig"},{"key":"2682_CR26","doi-asserted-by":"crossref","unstructured":"Rabi FA, Zoubi M, Kasasbeh G, Salameh D, Al-Nasser A. SARS-CoV-2 and coronavirus disease 2019: what we know so Far. Pathogens. 2020;9(231).","DOI":"10.3390\/pathogens9030231"},{"key":"2682_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565\u201374.","journal-title":"Lancet"},{"issue":"9","key":"2682_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/CM9.0000000000000819","volume":"133","author":"PF Wei","year":"2020","unstructured":"Wei PF. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 7). Chin Med J (Engl). 2020;133(9):1087\u201395.","journal-title":"Chin Med J (Engl)"},{"key":"2682_CR29","doi-asserted-by":"publisher","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China [Internet]. bioRxiv; 2020 [cited 2025 Jun 25]. p. 2020.01.24.919183. Available from: https:\/\/www.biorxiv.org\/content\/https:\/\/doi.org\/10.1101\/2020.01.24.919183v2","DOI":"10.1101\/2020.01.24.919183v2"},{"key":"2682_CR30","doi-asserted-by":"crossref","unstructured":"Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications [Internet]. 2020. Available from: medRxiv.","DOI":"10.1101\/2020.03.30.20047365"},{"issue":"3","key":"2682_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325\u20138.","journal-title":"Cell Host Microbe"},{"key":"2682_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable Bat origin. Nature. 2020;579:270\u20133.","journal-title":"Nature"},{"key":"2682_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00011-020-01352-y","volume":"69","author":"VV Oberemok","year":"2020","unstructured":"Oberemok VV, Laikova K, Yurchenko K, Fomochkina I, Kubyshkin A. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship. Inflamm Res. 2020;69:635\u201340.","journal-title":"Inflamm Res"},{"issue":"7798","key":"2682_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139.","journal-title":"Nature"},{"key":"2682_CR35","doi-asserted-by":"crossref","unstructured":"Naqvi A, Fatima K, Mohammad T, Fatima U, Singh I, Singh A et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. BBA - Mol Basis Dis. 2020;1866(165878).","DOI":"10.1016\/j.bbadis.2020.165878"},{"key":"2682_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication and pathogenesis. J Med Virol. 2020;92:418\u201323.","journal-title":"J Med Virol"},{"key":"2682_CR37","doi-asserted-by":"crossref","unstructured":"Ju X, Zhu Y, Wang Y, Li J, Zhang J, Gong M et al. A novel culture system modeling the SARS-CoV-2 life cycle. PLoS Pathog. 2021;17(3).","DOI":"10.1371\/journal.ppat.1009439"},{"issue":"5","key":"2682_CR38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/pathogens9050331","volume":"9","author":"L Alanagreh","year":"2020","unstructured":"Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its Origin, Characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9(5):331.","journal-title":"Pathogens"},{"issue":"16","key":"2682_CR39","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"BJ Bosch","year":"2003","unstructured":"Bosch BJ, van der Zee R, de Haan CAM, Rottier PJM. The coronavirus Spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801\u201311.","journal-title":"J Virol"},{"issue":"9","key":"2682_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 Spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"2682_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.coi.2005.05.009","volume":"17","author":"Y Lau","year":"2005","unstructured":"Lau Y, Peiris J. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol. 2005;17:404\u201310.","journal-title":"Curr Opin Immunol"},{"key":"2682_CR42","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1128\/JVI.00311-12","volume":"86","author":"A Demogines","year":"2012","unstructured":"Demogines A, Farzan M, Sawyer S. Evidence of ACE2-Utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats. J Virol. 2012;86:6350\u20133.","journal-title":"J Virol"},{"key":"2682_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.","journal-title":"Cell"},{"key":"2682_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1073\/pnas.2200592119","volume":"119","author":"AM Syed","year":"2022","unstructured":"Syed AM, Ciling A, Taha T, Chen I, Khalid M, Sreekumar B, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. PNAS. 2022;119:31.","journal-title":"PNAS"},{"key":"2682_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.aivir.2016.08.005","volume":"96","author":"B Neuman","year":"2016","unstructured":"Neuman B, Buchmeier M. Supramolecular architecture of the coronavirus particle. Adv Vurus Res. 2016;96:1\u201327.","journal-title":"Adv Vurus Res"},{"issue":"3","key":"2682_CR46","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbrc.2020.04.136","volume":"527","author":"WLG Zeng","year":"2020","unstructured":"Zeng WLG, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527(3):618\u201323.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"2682_CR47","doi-asserted-by":"publisher","first-page":"10669","DOI":"10.1074\/jbc.M509233200","volume":"281","author":"M Surjit","year":"2006","unstructured":"Surjit M, Liu B, Chow VTK, Lal SK. The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells. J Biol Chem. 2006;281(16):10669\u201381.","journal-title":"J Biol Chem"},{"key":"2682_CR48","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1128\/JVI.01331-15","volume":"89","author":"L Cui","year":"2015","unstructured":"Cui L, Wang H, Ji Y, Yang J, Xu S, Huang X, et al. The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA Silencing in mammalian cells. J Virol. 2015;89:9029\u201343.","journal-title":"J Virol"},{"issue":"21","key":"2682_CR49","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1128\/JVI.01131-10","volume":"84","author":"AL Arndt","year":"2010","unstructured":"Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus membrane protein tail is important for virus assembly. J Virol. 2010;84(21):11418\u201328.","journal-title":"J Virol"},{"key":"2682_CR50","doi-asserted-by":"crossref","unstructured":"Yadav R, Chaudhary J, Jain N, Chaudhary P, Khanra S, Dhamija P et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells. 2021;10(821).","DOI":"10.3390\/cells10040821"},{"key":"2682_CR51","doi-asserted-by":"crossref","unstructured":"Tang T, Bidon M, Jaimes J, Whittaker G, Daniel S. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development. Antiviral Res. 2020;104792.","DOI":"10.1016\/j.antiviral.2020.104792"},{"issue":"1","key":"2682_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","volume":"174","author":"BW Neuman","year":"2011","unstructured":"Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11\u201322.","journal-title":"J Struct Biol"},{"issue":"2","key":"2682_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijmmb.2022.02.005","volume":"40","author":"V Ravi","year":"2022","unstructured":"Ravi V, Saxena S, Panda P. Basic virology of SARS-CoV-2. Indian J Med Microbiol. 2022;40(2):182\u20136.","journal-title":"Indian J Med Microbiol"},{"issue":"3","key":"2682_CR54","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/07391102.2021.2016490","volume":"41","author":"P Kumar","year":"2023","unstructured":"Kumar P, Kumar A, Garg N, Giri R. An insight into SARS-CoV-2 membrane protein interaction with spike, envelope, and nucleocapsid proteins. J Biomol Struct Dyn. 2023;41(3):1062\u201371.","journal-title":"J Biomol Struct Dyn"},{"key":"2682_CR55","doi-asserted-by":"crossref","unstructured":"Boson B, Legros V, Zhou B, Siret E, Mathieu C, Cosset F et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the Spike protein, allowing assembly of virus-like particles. J Biol Chem. 2021;296.","DOI":"10.1074\/jbc.RA120.016175"},{"issue":"7477","key":"2682_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nature12711","volume":"503","author":"XY Ge","year":"2013","unstructured":"Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a Bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535\u20138.","journal-title":"Nature"},{"key":"2682_CR57","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.peptides.2005.01.009","volume":"26","author":"F Gembardt","year":"2005","unstructured":"Gembardt F, Sterner-Kock A, Imboden H, Spalteholz M, Reibitz F, Schultheiss H, et al. Organ-specific distribution if ACE2 mRNA and correlating peptidase activity in rodents. Peptides. 2005;26:1270\u20137.","journal-title":"Peptides"},{"key":"2682_CR58","doi-asserted-by":"publisher","first-page":"148517","DOI":"10.1172\/JCI148517","volume":"131","author":"JH Ahn","year":"2021","unstructured":"Ahn JH, Kim J, Hong S, Choi S, Yang M, Ju Y, et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest. 2021;131:148517.","journal-title":"J Clin Invest"},{"key":"2682_CR59","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1016\/j.cell.2021.10.027","volume":"184","author":"M Khan","year":"2021","unstructured":"Khan M, Yoo S, Clijisters M, Backaert W, Vanstapel A, Speleman K, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosa but spares the olfactory bulb. Cell. 2021;184:5932\u201349.","journal-title":"Cell"},{"key":"2682_CR60","doi-asserted-by":"publisher","first-page":"708264","DOI":"10.3389\/fimmu.2021.708264","volume":"12","author":"N Redondo","year":"2021","unstructured":"Redondo N, Zaldivar-Lopez S, Garrido JJ, Montoya M. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front Immunol. 2021;12:708264.","journal-title":"Front Immunol"},{"key":"2682_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41577-021-00656-2","volume":"22","author":"LR Wong","year":"2022","unstructured":"Wong LR, Periman S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? Nat Rev Immunol. 2022;22:47\u201356.","journal-title":"Nat Rev Immunol"},{"key":"2682_CR62","doi-asserted-by":"crossref","unstructured":"Plescia CB, David E, Patra D, Sengupta R, Amiar S, Su Y et al. SARS-CoV-2 viral budding and entry can be modelled using BSL-2 level virus-like particles. J Biol Chem. 2021;296(100103).","DOI":"10.1074\/jbc.RA120.016148"},{"key":"2682_CR63","unstructured":"Trapotsis A. Laboratory Biosafety Level Checklist & Microbe Guide [Internet]. 2022. Available from: https:\/\/consteril.com\/wp-content\/uploads\/2017\/03\/CSS_Laboratory_Checklist-1.pdf"},{"key":"2682_CR64","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1128\/JVI.78.19.10628-10635.2004","volume":"78","author":"M Moore","year":"2004","unstructured":"Moore M, Dorfman T, Li W, Wong S, Li Y, Kuhn J, et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus Spike protein efficiently infect cells expressing-converting enzyme 2. J Virol. 2004;78:10628\u201335.","journal-title":"J Virol"},{"key":"2682_CR65","doi-asserted-by":"crossref","unstructured":"Tandon R, Mitra D, Sharma P, McCandless M, Stray S, Bates J et al. Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 Spike glycoprotein. Sci Rep. 2020;10(19076).","DOI":"10.1038\/s41598-020-76135-w"},{"key":"2682_CR66","doi-asserted-by":"crossref","unstructured":"Xu R, Shi M, Li J, Song P, Li N. Construction of SARS-CoV-2 Virus-Like particles by mammalian expression system. Front Bioeng Biotechnol. 2020;8(862).","DOI":"10.3389\/fbioe.2020.00862"},{"issue":"17","key":"2682_CR67","doi-asserted-by":"publisher","first-page":"9007","DOI":"10.1128\/JVI.78.17.9007-9015.2004","volume":"78","author":"T Giroglou","year":"2004","unstructured":"Giroglou T, Cinatl J, Rabenau H, Drosten C, Scwalbe H, Doerr H, et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol. 2004;78(17):9007\u201315.","journal-title":"J Virol"},{"issue":"21","key":"2682_CR68","doi-asserted-by":"publisher","first-page":"01062","DOI":"10.1128\/JVI.01062-20","volume":"94","author":"M Johnson","year":"2020","unstructured":"Johnson M, Lyddon T, Suarez R, Salcedo B, LePique M, Graham M, et al. Optimized pseudotyping conditions for the SARS-COV-2 Spike glycoprotein. J Virol. 2020;94(21):01062\u201320.","journal-title":"J Virol"},{"key":"2682_CR69","doi-asserted-by":"crossref","unstructured":"Zheng Y, Larragoite E, Williams E, Lama J, Cisneros I, Delgado J et al. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 Spike pseudotyped murine leukemia virions. Virol J. 2021;18(1).","DOI":"10.1186\/s12985-020-01472-1"},{"key":"2682_CR70","doi-asserted-by":"crossref","unstructured":"Millet J, Whittaker G. Murine leukemia virus (MLV)-based coronavirus Spike-pseudotyped particle production and infection. Bio Protoc. 2016;6(23).","DOI":"10.21769\/BioProtoc.2035"},{"key":"2682_CR71","doi-asserted-by":"crossref","unstructured":"Millet J, Tang T, Nathan L, Jaimes J, Hsu H, Daniel S et al. Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting. J Vis Exp. 2019;145.","DOI":"10.3791\/59010"},{"key":"2682_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11262-022-01890-z","volume":"58","author":"S Lee","year":"2022","unstructured":"Lee S, Kim D, Jung Y. Construction of SARS CoV 2 Spike pseudotyped retroviral vector inducing syncytia formation. Virus Genes. 2022;58:172\u20139.","journal-title":"Virus Genes"},{"issue":"6","key":"2682_CR73","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41418-021-00795-y","volume":"28","author":"L Lin","year":"2021","unstructured":"Lin L, Li Q, Wang Y, Shi Y. Syncytia formation during SARS-CoV-2 lung infection: a disastrous unity to eliminate lymphocytes. Cell Death Differ. 2021;28(6):2019\u201321.","journal-title":"Cell Death Differ"},{"issue":"4","key":"2682_CR74","doi-asserted-by":"publisher","first-page":"0301330","DOI":"10.1371\/journal.pone.0301330","volume":"19","author":"PB Purwono","year":"2024","unstructured":"Purwono PB, Vacharathit V, Manopwisedjaroen S, Ludowyke N, Suksatu A, Thitithanyanont A. Infection kinetics, syncytia formation, and inflammatory biomarkers as predictive indicators for the pathogenicity of SARS-CoV-2 variants of concern in Calu-3 cells. PLoS ONE. 2024;19(4):0301330.","journal-title":"PLoS ONE"},{"issue":"13","key":"2682_CR75","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.3390\/ijms26136462","volume":"26","author":"B Kratzer","year":"2025","unstructured":"Kratzer B, Gattinger P, Tauber PA, Schaar M, Sehgal ANA, Kraus A, et al. Moloney murine leukemia Virus-like nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for vaccination against COVID-19. Int J Mol Sci. 2025;26(13):6462.","journal-title":"Int J Mol Sci"},{"key":"2682_CR76","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1099\/vir.0.80955-0","volume":"86","author":"S Fukushi","year":"2005","unstructured":"Fukushi S, Mizutani T, Saijo M, Matsuyama S, Mikyajima N, Taguchi F. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus Spike protein. J Gen Virol. 2005;86:2269\u201374.","journal-title":"J Gen Virol"},{"key":"2682_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-59745-181-9_23","volume":"454","author":"S Fukushi","year":"2007","unstructured":"Fukushi S, Watanabe R, Taguchi F. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus Spike proteins. Methods Mol Biol. 2007;454:331\u20138.","journal-title":"Methods Mol Biol"},{"key":"2682_CR78","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680\u20136.","journal-title":"Microbes Infect"},{"key":"2682_CR79","doi-asserted-by":"publisher","first-page":"817200","DOI":"10.3389\/fmicb.2021.817200","volume":"12","author":"M Salazar-Garcia","year":"2022","unstructured":"Salazar-Garcia M, Acosta-Contreras S, Rodriguez-Martinez G, Cruz-Rangel A, Flores-Alanis A, Patino-Lopez G. Pseudotyped vesicular stomatitis Virus-Severe acute respiratory Syndrome-Coronavirus-2 Spike for the study of Variants, Vaccines, and therapeutics against coronavirus disease 2019. Front Microbiol. 2022;12:817200.","journal-title":"Front Microbiol"},{"key":"2682_CR80","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/v13040633","volume":"13","author":"Y Kim","year":"2021","unstructured":"Kim Y, Jang U, Soh S, Lee J, Lee H. The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 pseudovirus. Viruses. 2021;13:633.","journal-title":"Viruses"},{"key":"2682_CR81","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1016\/j.cell.2021.04.025","volume":"184","author":"X Deng","year":"2021","unstructured":"Deng X, Garcia-Knight M, Khalid M, Sevellita V, Wang C, Morris M, et al. Transmission, infectivity, and neutralization of a Spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426\u201337.","journal-title":"Cell"},{"key":"2682_CR82","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1038\/s41467-021-25168-4","volume":"12","author":"A West","year":"2021","unstructured":"West A, Werheim J, Wang J, Vasylyeva T, Havens J, Chowdhury M, et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in new York. Nat Commun. 2021;12:4886.","journal-title":"Nat Commun"},{"issue":"5","key":"2682_CR83","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/v12050513","volume":"12","author":"K Crawford","year":"2020","unstructured":"Crawford K, Eguia R, Dingens A, Loes A, Malone K, Wolf C, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. Viruses. 2020;12(5):513.","journal-title":"Viruses"},{"issue":"16","key":"2682_CR84","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.21769\/BioProtoc.4194","volume":"11","author":"L Mekkaoui","year":"2021","unstructured":"Mekkaoui L, Bentley E, Ferrari M, Lamb K, Ward K, Karattil R, et al. Optimised method for the production and Titration of lentiviral vectors pseudotyped with the SARS-CoV-2 Spike. Bio-Protoc. 2021;11(16):4194.","journal-title":"Bio-Protoc"},{"key":"2682_CR85","doi-asserted-by":"crossref","unstructured":"Lei C, Qian K, Li T, Zhang S, Fu W, Ding M et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(2070).","DOI":"10.1038\/s41467-020-16048-4"},{"issue":"1","key":"2682_CR86","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jtcme.2021.09.002","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, Pan Y, Wu T, Yao T, Wang W, Shen W, et al. Potential natural products that target the SARS-CoV-2 Spike protein identified by structure-based virtual screening, isothermal Titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay. J Tradit Complement Med. 2022;12(1):73\u201389.","journal-title":"J Tradit Complement Med"},{"key":"2682_CR87","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","volume":"186","author":"B Dadonaite","year":"2023","unstructured":"Dadonaite B, Crawford K, Radford C, Farrell A, Yu T, Hannon W, et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 Spike. Cell. 2023;186:1263\u201378.","journal-title":"Cell"},{"key":"2682_CR88","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.jbc.2021.100306","volume":"296","author":"A Bayati","year":"2021","unstructured":"Bayati A, Kumar R, Francis V, McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296:100306.","journal-title":"J Biol Chem"},{"issue":"8","key":"2682_CR89","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/biomedicines12081885","volume":"12","author":"S Fernandez","year":"2024","unstructured":"Fernandez S, Pelaez-Prestel H, Ras-Carmona A, Mozas-Gutierrez J, Reyes-Manzanas R, Reche P. Eucalyptus essential oil inhibits cell infection by SARS-CoV-2 Spike pseudotyped lentivirus. Biomedicines. 2024;12(8):1885.","journal-title":"Biomedicines"},{"key":"2682_CR90","doi-asserted-by":"crossref","unstructured":"Kumar B, Hawkins G, Kicmal T, Qing E, Timm E, Gallagher T. Assembly and entry of severe acute respiratory syndrome coronavirus (SARS-CoV-2): evaluation using Virus-Like particles. Cells. 2021;10(853).","DOI":"10.3390\/cells10040853"},{"key":"2682_CR91","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.abl6184","volume":"374","author":"AM Syed","year":"2021","unstructured":"Syed AM, Taha T, Tabata T, Chen I, Ciling A, Khalid M, et al. Rapid assessment of SARS-CoV-2\u2013evolved variants using virus-like particles. Science. 2021;374:1626\u201332.","journal-title":"Science"},{"key":"2682_CR92","doi-asserted-by":"crossref","unstructured":"Gourdelier M, Swain J, Arone C, Mouttou A, Bracquemond D, Merida P et al. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles. Nat Sci Rep. 2022;12(14651).","DOI":"10.1038\/s41598-022-18681-z"},{"issue":"1","key":"2682_CR93","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","volume":"11","author":"Y Yahalom-Ronen","year":"2020","unstructured":"Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. A single dose of Recombinant VSV-\u2206G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):6402.","journal-title":"Nat Commun"},{"issue":"6","key":"2682_CR94","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/v15061364","volume":"15","author":"Y Yahalom-Ronen","year":"2023","unstructured":"Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Achdout H, Erez N, et al. VSV-\u2206G-Spike candidate vaccine induces protective immunity and protects K18-hACE2 mice against SARS-CoV-2 variants. Viruses. 2023;15(6):1364.","journal-title":"Viruses"},{"issue":"5","key":"2682_CR95","doi-asserted-by":"publisher","first-page":"eadq4545","DOI":"10.1126\/sciadv.adq4545","volume":"11","author":"RA Adeleke","year":"2025","unstructured":"Adeleke RA, Sahler J, Choi A, Roth K, Upadhye V, Ezzatpour S, et al. Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus. Sci Adv. 2025;11(5):eadq4545.","journal-title":"Sci Adv"},{"issue":"15","key":"2682_CR96","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.vaccine.2021.12.063","volume":"40","author":"KW Peng","year":"2022","unstructured":"Peng KW, Carey T, Lech P, Vandergaast R, Mu\u00f1oz-Al\u00eda M\u00c1, Packiriswamy N, et al. Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Vaccine. 2022;40(15):2342\u201351.","journal-title":"Vaccine"},{"issue":"1","key":"2682_CR97","doi-asserted-by":"publisher","first-page":"101189","DOI":"10.1016\/j.omtm.2024.101189","volume":"32","author":"H Todesco","year":"2024","unstructured":"Todesco H, Gafuik C, John C, Roberts E, Borys B, Pawluk A, et al. High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors. Mol Ther Methods Clin Dev. 2024;32(1):101189.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"2682_CR98","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)80436-5","volume":"91","author":"Z Ivics","year":"1997","unstructured":"Ivics Z, Hacket P, Plasterk R, Izsvak Z. Molecular reconstruction of sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91(4):501\u201310.","journal-title":"Cell"},{"issue":"10","key":"2682_CR99","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpz1.575","volume":"2","author":"V Pszenny","year":"2022","unstructured":"Pszenny V, Tjhin E, Alves-Ferreira E, Spada S, Bouamr F, Nair V, et al. Using the sleeping beauty (SB) transposon to generate stable cells producing enveloped Virus-Like particles (eVLPs) pseudotyped with SARS\u2010CoV\u20102 proteins for vaccination. Curr Protoc. 2022;2(10):575.","journal-title":"Curr Protoc"},{"key":"2682_CR100","doi-asserted-by":"crossref","unstructured":"Bommireddy R, Stone S, Bhatnager N, Kumari P, Munoz L, Oh J et al. Influenza Virus-like Particle-Based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses. Vaccines. 2022;10(944).","DOI":"10.3390\/vaccines10060944"},{"key":"2682_CR101","doi-asserted-by":"crossref","unstructured":"Geng QTW, Baxter VK, Shi J, Wan Y. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathog. 2021;17(9).","DOI":"10.1371\/journal.ppat.1009897"},{"key":"2682_CR102","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812\u201327.","journal-title":"Cell"},{"issue":"9","key":"2682_CR103","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/vaccines10091545","volume":"10","author":"H Ke","year":"2022","unstructured":"Ke H, Chang M, Marasco W. Immune evasion of SARS-CoV-2 Omicron subvariants. Vaccines. 2022;10(9):1545.","journal-title":"Vaccines"},{"issue":"2","key":"2682_CR104","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","volume":"4","author":"M Azeem","year":"2023","unstructured":"Azeem M, Nooka A, Shanmugasundaram U, Cheedarla N, Potdar S, Manalo R, et al. Impaired SARS-CoV-2 variant neutralization and CD8\u2009+\u2009T-cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections. Blood Cancer Discov. 2023;4(2):106\u201317.","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"2682_CR105","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/TP.0000000000004140","volume":"106","author":"A Karaba","year":"2022","unstructured":"Karaba A, Johnston T, Aytenfisu T, Akinde O, Eby Y, Ruff J, et al. A fourth dose of COVID-19 vaccine does not induce neutralization of the Omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation. 2022;106(7):1440\u20134.","journal-title":"Transplantation"},{"key":"2682_CR106","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","volume":"28","author":"H Tegally","year":"2022","unstructured":"Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28:1785\u201390.","journal-title":"Nat Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02682-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:02:20Z","timestamp":1774555340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02682-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}